Track Bioxytran's accounts payable ($680) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
Bioxytran (BIXT) currently reports a accounts payable of $680 as of June 2026. That compares with $690K in the prior-year period — down 99.9% year over year. Use the charts on this page to explore Bioxytran's accounts payable history and peer comparisons.
Bioxytran's accounts payable decreased from $690K to $680 — a 99.9% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Bioxytran reported $680 in accounts payable as of June 2026. That compares with $690K in the prior-year period — down 99.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current accounts payable of $680, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Bioxytran, and consider following BIXT for alerts when major investors trade the stock.
Bioxytran is classified in the Healthcare sector. On accounts payable, it currently shows $680. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BIXT with unrelated industries.